Breaking News
February 17, 2019 - Exercise gives a better brain boost to older men than women
February 17, 2019 - New research disproves previous assumptions of how looks influence personality
February 17, 2019 - Cannabis use as a teenager linked to depression later in life
February 17, 2019 - Sinks by Toilets in ICU Patient Rooms Harbor Harmful Bacteria
February 17, 2019 - Cancer cells’ plasticity makes them harder to stop
February 17, 2019 - Young cannabis users have increased risk of depression and suicidal behavior
February 17, 2019 - Tasmanian Devils Likely to Survive Cancer Scourge
February 17, 2019 - Neoadjuvant PD-1 blockade seems effective in glioblastoma
February 17, 2019 - Personal, social factors play role in enabling sustainable return to work after ill health
February 17, 2019 - Mouse studies show ‘inhibition’ theory of autism wrong
February 17, 2019 - Study shows how neuroactive steroids inhibit activity of pro-inflammatory proteins
February 17, 2019 - Use of liver grafts from older donors decreased despite better outcomes in recipients
February 17, 2019 - MUSC researchers discover new mechanism for a class of anti-cancer drugs
February 17, 2019 - HPV misconceptions are causing women to miss smear tests
February 17, 2019 - Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
February 17, 2019 - Researchers say auditory testing can identify children for autism screening
February 17, 2019 - New method analyzes how single biological cells react to stressful situations
February 17, 2019 - WVU gynecologic oncologist investigates novel treatment for cervical and vaginal cancers
February 17, 2019 - ADHD diagnoses poorly documented
February 17, 2019 - Majority of gender minority youth do not identify with traditional sexual identity labels
February 17, 2019 - AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
February 17, 2019 - Lower Birth Weight May Up Risk for Psychiatric Disorders
February 17, 2019 - Scientists identify reversible molecular defect underlying rheumatoid arthritis
February 17, 2019 - Moffitt researchers shed light on how CAR T cells function mechanistically
February 16, 2019 - Female Anatomy May Play Big Role in Sperm’s Success
February 16, 2019 - BMI may mediate inverse link between fiber intake, knee OA
February 16, 2019 - Movement impairments in autism can be reversed through behavioral training
February 16, 2019 - Studies address racial disparities in postpartum period and cardiovascular health
February 16, 2019 - Scientists implicate hidden genes in the severity of autism symptoms
February 16, 2019 - Decreased deep sleep linked to early signs of Alzheimer’s disease
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - Children with ASD more likely to face maltreatment, study finds
February 16, 2019 - Study finds genetic vulnerability to use of menthol cigarettes
February 16, 2019 - Promising drug developed to rejuvenate muscle cells
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
February 16, 2019 - Conformance of genetic characteristics found to be crucial for longer preservation of kidney graft
February 16, 2019 - Researchers use optogenetic tool to control, visualize receptor signals in neural cells
February 16, 2019 - New reversible antiplatelet therapy could reduce risk of blood clots, prevent cancer metastasis
February 16, 2019 - Testosterone is not the only hormone needed for penis development
February 16, 2019 - FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression
February 15, 2019 - Heart surgery technology developed at Baptist Health debuts after years of secrecy
February 15, 2019 - Prescription Opioids Double Risk of Triggering Fatal Car Crash
February 15, 2019 - New study helps doctors better understand high blood pressure in pregnant women
February 15, 2019 - Beta wave control in Parkinson’s diseased brain could be a potential therapy
February 15, 2019 - Media representations of love may justify gender-based violence in young people
Physician-scientists present updated efficacy data on CAR T-cell gene immunotherapy

Physician-scientists present updated efficacy data on CAR T-cell gene immunotherapy

image_pdfDownload PDFimage_print

Physician-scientists from Children’s Hospital of Philadelphia (CHOP) presented updated efficacy and safety data on Kymriah(R)* (tisagenlecleucel, formerly CTL019) –the first-ever U.S. Food and Drug Administration (FDA) approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers at the 60th American Society of Hematology (ASH) annual meeting, as well as first-of-its-kind research on overcoming CAR T-cell resistance.

Together, the contributions further cement CHOP’s aggressive pursuit of giving patients better options in this new field of personalized, cellular medicine.

An updated, longer-term analysis of ELIANA, the first pediatric global CAR-T cell therapy registration trial of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL), shows an 82% remission rate within three months after a single infusion, and 62% relapse-free survival at 24 months, as presented by Stephan Grupp, MD, PhD, Director of the Cancer Immunotherapy Program and Section Chief of Cell Therapy and Transplant at CHOP, and a Professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania.

The safety profiles observed for Kymriah, pioneered together with Novartis and the Perelman School of Medicine at the University of Pennsylvania, remained consistent with previously reported results, with no emergence of new safety concerns.

“Before this personalized, cellular gene therapy, the patients we are treating with CAR T-cells had about a ten percent chance of surviving,” said Dr. Grupp. “To see this 82 percent remission rate in our patients is beyond what I ever imagined when we treated our first patient in 2012. Hundreds of patients later, we’re able to say those children who safely achieve durable remissions have a good chance of long-term disease control, and our hope is this is the last treatment they ever need.”

Chimeric antigen receptor T (CAR-T) cell therapy genetically modifies a patient’s immune cells to make them seek out and kill leukemia cells. The approach was developed by a team led by Carl June, MD, a professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of the Center for Cellular Immunotherapies in Penn’s Abramson Cancer Center. In 2012, Penn and Novartis entered into a global collaboration to further research, develop and commercialize Kymriah. CHOP was the first institution to use the therapy in children with leukemia.

In other data presented at ASH, CHOP researchers found for some patients who do not achieve durable responses to CAR T-cell therapy due to T-cell exhaustion or cell death, which may be generated by the body’s naturally occurring brake on the immune system, adding an inhibitor against the immune checkpoint PD-1 (programmed cell death 1) to CAR T-cell therapy could extend treatment response and improve outcomes for children with r/r ALL.

CHOP’s small, single-center study evaluated 14 children ranging in age from 4 to 17 years, all of whom had received CD19-directed CAR T-cell therapy, and were given pembrolizumab or nivolumab. With the addition of the PD-1 blockade, 50 percent of patients maintained either partial or complete disease responses, according to study lead Shannon Maude, MD, PhD, an oncologist and scientist in CHOP’s Cancer Immunotherapy Program.

“When we give a checkpoint inhibitor, it seems to release the body’s immune brakes on the

T-cell, allowing the T-cell to focus on its job of attacking cancer,” Dr. Maude said. “This combination therapy could overcome that resistance in some CAR T-cell patients. Understanding these are children who would otherwise have no other therapeutic options, maximizing the response of the therapy, and overcoming resistance, are critical.”

“Our unrivaled immunotherapy program treated the first patient, and now more patients than any other pediatric institution in the world, with this innovative therapy,” said Stephen Hunger, MD, Chief of the Division of Oncology and Director of the Center for Childhood Cancer Research at CHOP. “Now, equally exciting, our clinical and research teams continue to move the dial, looking for ways to improve upon CAR T-cell therapy so even more young cancer patients benefit from it. Our institution remains unsurpassed in its efforts to introduce and perfect new gene therapies.”

Dr. Grupp, Dr. Maude and their team will continue following these patients and exploring combination strategies to improve outcomes after CAR T-cell therapy, as more clinical research trials are underway at CHOP to further improve CAR T-cell therapy and apply it for use in more pediatric cancers.

Tagged with:

About author

Related Articles